• RAS/PI3K Mutations Sensitize Ovarian Cancer to PARP/NAMPT In

  2026-06-02

  This study demonstrates that epithelial ovarian cancer cells harboring RAS/PI3K pathway mutations are particularly sensitive to combined PARP and NAMPT inhibition. These findings highlight potential biomarker-driven strategies to overcome resistance in high-grade serous carcinoma and suggest new avenues for rational combination therapies.

• HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit: Evidence &

  2026-06-01

  The HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit enables efficient, fluorescent RNA probe synthesis with tunable Cy5-UTP incorporation for sensitive hybridization assays. This article critically examines its biochemical rationale, compares benchmarks, and provides structured workflow parameters for optimal research use.

• ABT-199 (Venetoclax): Next-Gen Bcl-2 Inhibition for Translat

  2026-06-01

  This thought-leadership article explores the mechanistic, experimental, and translational landscape of ABT-199 (Venetoclax) as a potent, highly selective Bcl-2 inhibitor. Integrating recent evidence from aging and neuroinflammation research, including the modulation of microglial senescence, we provide strategic guidance for translational researchers. The discussion contextualizes ABT-199 within the competitive apoptosis assay landscape, details protocol considerations, and projects future directions for hematologic and cross-disciplinary models. APExBIO’s ABT-199 is showcased as a gold-standard research tool, with an emphasis on its selectivity and translational utility.

• Puerarin Regulates Gut Microbiota and Thermogenesis in T2D M

  2026-05-31

  This study demonstrates that puerarin, a bioactive compound from Pueraria lobata, improves glucose and lipid metabolism in Type 2 diabetes (T2D) mice by restoring gut microbiota balance and enhancing adipose tissue thermogenesis. These findings highlight novel mechanistic links between phytotherapy, metabolic regulation, and the gut-adipose axis, with translational implications for T2D management.

• Indole-3-pyruvic Acid: Applied Workflows in Immune and Plant

  2026-05-30

  Indole-3-pyruvic acid (IPA) is a pivotal metabolic intermediate enabling advanced plant hormone and immune modulation assays. Harness robust, reproducible results with APExBIO's IPA through literature-backed workflows, actionable parameters, and troubleshooting strategies tailored to both plant and mammalian systems.

• Sumatriptan Succinate: Applied Workflows for 5-HT1 Research

  2026-05-29

  Sumatriptan Succinate stands out as a selective 5-HT1B/1D receptor agonist, empowering migraine and neuroinflammation research with robust, reproducible workflows. This article delivers practical protocol enhancements, advanced troubleshooting, and contextualizes the latest metabolism findings to maximize translational impact.

• Angiotensin II (A1042): Technical Guidance for Vascular Rese

  2026-05-29

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) supports researchers modeling hypertension, vascular remodeling, and smooth muscle cell hypertrophy where a defined, potent GPCR agonist is required. This product should not be used for diagnostic or therapeutic purposes, and long-term solution storage is not recommended due to peptide instability.

• FK866 (APO866) in Hematologic Cancer: Protocols & Pitfalls

  2026-05-28

  FK866 (APO866) is redefining hematologic cancer research by enabling precise NAD biosynthesis inhibition and selective cytotoxicity in AML models. This guide delivers actionable workflows, protocol optimizations, and troubleshooting strategies, empowering researchers to leverage FK866’s high specificity and unique cell death mechanisms for reproducible, mechanistic insights.

• Anti Reverse Cap Analog (ARCA): Driving Next-Gen mRNA Therap

  2026-05-28

  Discover how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, is revolutionizing synthetic mRNA design by enabling ultra-efficient, orientation-specific capping for advanced therapeutics. This in-depth article explores unique translational and stem cell engineering insights not found elsewhere.

• Synthetic mRNA-Driven Differentiation of hiPSCs into Oligode

  2026-05-27

  The referenced study demonstrates a rapid, virus-free protocol for differentiating human-induced pluripotent stem cells (hiPSCs) into functional oligodendrocytes using a synthetic, modified OLIG2 mRNA. This innovation offers a safer, more efficient approach for generating oligodendrocyte lineage cells for disease modeling and regenerative therapies.

• Technical Guide: Annexin V-FITC/7-AAD Apoptosis Kit (K1139)

  2026-05-27

  The Annexin V-FITC/7-AAD Apoptosis Kit enables rapid, dual-parameter detection of apoptotic and necrotic cells for robust cell viability and cytotoxicity assays. It is best suited for standard fluorescence-based workflows using flow cytometry or microscopy, but is not recommended for mechanistic pathway analysis beyond phosphatidylserine exposure.

• Taltirelin Acetate: Sustained Neuroprotection and OSA Resear

  2026-05-26

  Taltirelin acetate, a long-acting TRH analog, empowers researchers to model neurodegenerative and sleep disorders with unprecedented pharmacological precision. Its sustained action, robust neuroprotection, and proven efficacy in OSA and itch models set it apart as an indispensable tool for translational neuroscience.

• Calnexin-Dependent Rescue of CFTR Variants: Mechanistic Insi

  2026-05-26

  Tedman et al. systematically dissect how the ER chaperone calnexin shapes plasma membrane expression and pharmacological rescue of over 200 clinical CFTR variants. Their findings clarify variant-specific dependencies on proteostasis machinery, offering mechanistic guidance for precision cystic fibrosis research and CFTR modulator development.

• Precision Fluorescent RNA Probes: From Mechanism to Strategy

  2026-05-25

  This thought-leadership article guides translational researchers through the mechanistic and strategic landscape of fluorescent RNA probe synthesis, spotlighting the HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit. Integrating recent insights into RNA-protein phase separation, the discussion bridges foundational biology with actionable, high-yield probe design, positioning APExBIO’s offering as a transformative solution for advanced hybridization and RNA-interaction studies.

• CP-673451: Pioneering Selective PDGFR Inhibition in Translat

  2026-05-25

  Explore how CP-673451, a highly selective PDGFRα/β inhibitor from APExBIO, is transforming translational cancer research. This article provides mechanistic insights, strategic protocol guidance, and a forward-looking perspective on the role of PDGFR inhibition in angiogenesis, tumor growth, and the emerging field of ATRX-deficient glioma therapeutics. We bridge foundational evidence with practical recommendations for optimizing preclinical models, while distinguishing this discussion from standard product literature through an integrated, evidence-based outlook.

399 records 6/27 page Previous Next First page 上5页 678910 下5页 Last page